TITLE

The failure of antibiotics to prevent heart attacks

AUTHOR(S)
Taylor-Robinson, David; Boman, Jens
PUB. DATE
August 2005
SOURCE
BMJ: British Medical Journal (International Edition);8/13/2005, Vol. 331 Issue 7513, p361
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Presents an editorial regarding the failure of antibiotics in the prevention of heart attacks. Discussion of two clinical trials regarding the role of the respiratory pathogen Chlamydia pneumoniae in causing atherosclerotic cardiovascular disease; Description of a trial by Grayston and colleagues of azithromycin or placebo taken by patients with stable coronary artery disease; Description of a trial by Cannon and colleagues of gatifloxacin or placebo taken by patients who were in hospital with an acute coronary syndrome; Report that in neither trial did antibiotic therapy reduce the occurrence of cardiovascular events.
ACCESSION #
17958612

 

Related Articles

  • Modular prevention of heart disease following acute coronary syndrome (ACS) [ISRCTN42984084]. Redfern, Julie; Ellis, Elizabeth; Briffa, Tom; Freedman, SB // BMC Cardiovascular Disorders;2006, Vol. 6, p26 

    Background: Coronary heart disease (CHD) is a major cause of morbidity and mortality in Australia and it is recommended that all persons with unstable angina (UA) or myocardial infarction (MI) participate in secondary prevention as offered in cardiac rehabilitation (CR) programs. However, the...

  • Chlamydia pneumoniae in the Atherosclerotic Plaques of Coronary Artery Disease Patients. Izadi, Morteza; Fazel, Mozhgan; Akrami, Mohsen; Saadat, Seyed Hassan; Pishgoo, Bahram; Nasseri, Mohammad Hassan; Dabiri, Hossein; SafiAryan, Reza; Esfahani, Ali Akbar; Ahmadi, Ali; Kazemi-Saleh, Davood; Kalantar-Motamed, Mohammad Hassan; Taheri, Saeed // Acta Medica Iranica;2013, Vol. 51 Issue 12, p864 

    An association between Chlamydia pneumoniae (C. pneumoniae) and cardiovascular disease has been demonstrated. In this study, we aimed to study this potential relationship in 105 Iranian patients. Coronary artery specimens from 105 Iranian patients undergoing CABG were analyzed by PCR method for...

  • Atorvastatin reduced coronary and stroke events in patients with hypertension and without dyslipidemia: COMMENTARY. Simon, Joel A. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p57 

    Except for the Antihypertensivc and Lipid-Lowering Heart Attack Trial (ALLHAT), which was non-blinded and suffered from the frequent use of statins among participants who were allocated to placebo, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) has joined other primary...

  • Far from the Heart: Receptor cross-talk in remote conditioning. Weber, Christian // Nature Medicine;Jul2010, Vol. 16 Issue 7, p760 

    The article discusses a clinical trial on remote ischemic conditioning that could help in reducing or preventing myocardial infarction. It cites the mechanisms that the researchers used in the study such as occlusion and reperfusion. It elaborates the role of cell as well as morphine and opioid...

  • Primary prevention with pravastatin for 5 years continued to prevent coronary events in the following 10 years. Eaton, Charles B. // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p5 

    The article focuses on the clinical trial investigating if five years of pravastatin treatment have long-term benefits for prevention of coronary heart disease (CHD) in middle-aged men with hypercholesterolemia and no history of myocardial infarction (MI). The trial, conducted with 6595 men (45...

  • Placing COURAGE in Context: Review of the Recent Literature on Managing Stable Coronary Artery Disease. Coylewright, Megan; Blumenthal, Roger S.; Post, Wendy // Mayo Clinic Proceedings;Jul2008, Vol. 83 Issue 7, p799 

    Coronary artery disease (CAD) is the leading cause of death in the United States, but prevention and intervention efforts are lowering mortality. This progress is being undercut by rising rates of obesity and diabetes, and adherence to evidence-based prevention efforts is less than ideal. Many...

  • Population Assessment of Future Trajectories in Coronary Heart Disease Mortality. Thorolfsdottir, Rosa Björk; Aspelund, Thor; Capewell, Simon; Critchley, Julia; Gudnason, Vilmundur; Andersen, Karl // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: Coronary heart disease (CHD) mortality rates have been decreasing in Iceland since the 1980s, largely reflecting improvements in cardiovascular risk factors. The purpose of this study was to predict future CHD mortality in Iceland based on potential risk factor trends. Methods and...

  • Impact of a Partial Smoke-Free Legislation on Myocardial Infarction Incidence, Mortality and Case-Fatality in a Population-Based Registry: The REGICOR Study. Agüero, Fernando; De´gano., Irene R.; Subirana, Isaac; Grau, Maria; Zamora, Alberto; Sala, Joan; Ramos, Rafel; Treserras, Ricard; Marrugat, Jaume; Elosua, Roberto // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Background and Objective: Coronary heart disease (CHD) is the leading cause of death, and smoking its strongest modifiable risk factor. Our aim was to determine the impact of the Spanish 2006 partial smoke-free legislation on acute myocardial infarction (AMI) incidence, hospitalization and...

  • New Hope for Ailing Hearts.  // Health (Time Inc. Health);May99, Vol. 13 Issue 4, p28 

    Presents information on a study which revealed that certain kinds of antibiotics such as tetracylines and quinolones can lower the risk of heart attacks. Information on a bacterium called Chlamydia pneumoniae which may triggered some cases of atherosclerosis; Clinical trials conducted on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics